Compare RGR & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGR | IVVD |
|---|---|---|
| Founded | 1949 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.9M | 437.1M |
| IPO Year | 1994 | 2021 |
| Metric | RGR | IVVD |
|---|---|---|
| Price | $43.53 | $1.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $43.00 | $8.75 |
| AVG Volume (30 Days) | 152.2K | ★ 2.0M |
| Earning Date | 03-02-2026 | 03-05-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $546,057,000.00 | $53,426,000.00 |
| Revenue This Year | $2.38 | $143.48 |
| Revenue Next Year | N/A | $25.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.94 | ★ 110.47 |
| 52 Week Low | $28.33 | $0.46 |
| 52 Week High | $48.21 | $3.07 |
| Indicator | RGR | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 75.69 | 44.56 |
| Support Level | $35.42 | $1.41 |
| Resistance Level | $45.33 | $1.77 |
| Average True Range (ATR) | 1.26 | 0.12 |
| MACD | 0.36 | -0.02 |
| Stochastic Oscillator | 95.84 | 29.84 |
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.